418,581 Shares in Agenus Inc. $AGEN Purchased by Globeflex Capital L P

Key Points

• Globeflex Capital acquired 418,581 Agenus shares worth approximately $1.28 million, representing about 0.93% of the biotechnology company. Other institutional investors also opened positions, with institutions collectively owning 61.46% of the stock.
• Analyst sentiment is mixed: Agenus has an average rating of “Hold” and an average price target of $19.50. HC Wainwright and B. Riley maintained “Buy” ratings, while other analysts downgraded the stock or maintained a “Sell” view.
• Agenus shares opened at $7.67, near their 52-week high of $8.85, after reporting quarterly revenue of $34.52 million but an adjusted loss of $0.01 per share that missed expectations. The company remains a clinical-stage immuno-oncology developer focused on cancer therapies.

Globeflex Capital L P acquired a new position in shares of Agenus Inc. (NASDAQ:AGEN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 418,581 shares of the biotechnology company's stock, valued at approximately $1,281,000. Globeflex Capital L P owned approximately 0.93% of Agenus as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. EP Wealth Advisors LLC purchased a new position in shares of Agenus in the 4th quarter worth approximately $31,000. R Squared Ltd purchased a new position in shares of Agenus during the 4th quarter valued at $41,000. Redwood Family Wealth LLC bought a new position in shares of Agenus during the 4th quarter worth $44,000. Quadrature Capital Ltd purchased a new stake in Agenus in the 4th quarter worth about $54,000. Finally, Squarepoint Ops LLC purchased a new stake in Agenus during the third quarter valued at about $54,000. Institutional investors own 61.46% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on AGEN shares. HC Wainwright restated a "buy" rating and issued a $25.00 target price (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of Agenus from a "strong-buy" rating to a "hold" rating in a report on Monday, August 17th. Weiss Ratings lowered shares of Agenus from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday. Zacks Research lowered shares of Agenus from a "strong-buy" rating to a "hold" rating in a report on Monday, May 11th. Finally, B. Riley Financial reaffirmed a "buy" rating and set a $14.00 target price (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $19.50.

Agenus Stock Performance

Shares of Agenus stock opened at $7.67 on Tuesday. Agenus Inc. has a 52-week low of $2.71 and a 52-week high of $8.85. The stock has a market capitalization of $345.30 million, a price-to-earnings ratio of 2.97 and a beta of 1.41. The company has a fifty day moving average of $5.38 and a 200-day moving average of $4.15.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%.The company had revenue of $34.52 million for the quarter, compared to the consensus estimate of $34.00 million. On average, equities research analysts forecast that Agenus Inc. will post -0.28 earnings per share for the current fiscal year.

Agenus Company Profile

Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source